Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals
- PMID: 30531314
- PMCID: V体育安卓版 - PMC6374101
- DOI: 10.1097/QAD.0000000000002083
Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals (VSports最新版本)
Abstract
Objectives: Reversing HIV-1 latency has been suggested as a strategy to eradicate HIV-1. We investigated the effect of romidepsin on the HIV transcription profile in participants from the REDUC part B clinical trial. VSports手机版.
Design: Seventeen participants on suppressive antiretroviral therapy were vaccinated with six doses of the therapeutic vaccine Vacc-4x followed by treatment with three doses of romidepsin. Samples from nine study participants were available for HIV transcription profile analysis. V体育安卓版.
Methods: Read-through, total (TAR), elongated (longLTR), polyadenylated (polyA) and multiply-spliced (Tat-Rev) HIV transcripts and total HIV DNA were quantified at baseline (visit 1) and 4 h after the second (visit 10b) and third (visit 11b) romidepsin infusions V体育ios版. .
Results: Read-through, total, elongated, and polyadenylated HIV transcripts increased after romidepsin infusion (P = 0. 020, P = 0. 0078, P = 0. 0039, P = 0. 027, respectively), but no changes were observed in multiply-spliced HIV RNA or HIV DNA. No change was observed in the ratio of read-through/total HIV transcripts. The ratio of elongated/total HIV RNA increased after romidepsin (P = 0 VSports最新版本. 016), whereas the ratio of polyadenylated/elongated HIV decreased. Both elongated HIV transcripts and total HIV DNA correlated negatively with the time to viral rebound after interruption of ART. .
Conclusions: In these patients, romidepsin increased early events in HIV transcription (initiation and especially elongation), but had less effect on later stages (completion, multiple splicing) that may be required for comprehensive latency reversal and cell killing. Without cell death, increased HIV transcription before or after latency reversal may hasten viral rebound after therapy interruption. V体育平台登录.
Conflict of interest statement
Conflict of interest:
Bionor Pharma sponsored the clinical study from which these samples were derived and contributed to the design of the clinical trial VSports注册入口. The funders had no role in data collection and analysis, decision to publish, or preparation of the manuscript. The remaining authors declare no conflict of interest.
Figures


References (V体育ios版)
-
- Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278(5341):1291–1295. - PubMed
-
- Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278(5341):1295–1300. - "V体育ios版" PubMed
Publication types
- "VSports在线直播" Actions
"VSports app下载" MeSH terms
- "VSports最新版本" Actions
- Actions (V体育ios版)
- Actions (V体育2025版)
- "VSports在线直播" Actions
- "VSports最新版本" Actions
- "V体育2025版" Actions
- Actions (VSports注册入口)
- Actions (VSports app下载)
V体育官网 - Substances
- "VSports手机版" Actions